- myelodysplastic syndromes (MDS)
Lenalidomide is a capsule that is taken by mouth. It is approved for treating low-risk, transfusion-dependent myelodysplastic syndrome (MDS) patients with an abnormality of chromosome 5q. It is currently in clinical trials to test its efficacy with a broader range of MDS patients. For some MDS patients, lenalidomide can improve anemia and reduce or eliminate the need for blood transfusions.